There is no single blood-sugar effect that can be assigned to every product described as NAD+ support. Studies involve different ingredients, populations and outcomes. Some findings concern insulin sensitivity in muscle; others concern adverse effects from high-dose niacin.[1][2]
Those results need to stay attached to the compound that was studied.
What did the NMN trial measure?
A 10-week randomized trial studied NMN in postmenopausal women with prediabetes who had overweight or obesity. Insulin-stimulated glucose disposal and muscle insulin signaling increased after NMN treatment; they did not change after placebo.[1]
The measurement used a specialized research method. The finding concerns muscle insulin sensitivity in that group, not demonstrated diabetes treatment with NAD+ injections.[1]
Why can niacin raise a different concern?
At high supplemental amounts, nicotinic acid can impair glucose tolerance and increase insulin resistance. NIH guidance discusses checking glucose or HbA1c alongside other safety measurements in that setting.[2]
That adverse-effect evidence concerns nicotinic acid. It should not be used to declare that every NAD+ precursor raises glucose, just as the NMN trial should not be used to promise that every precursor lowers it.[1][2]
Which glucose result answers the clinical question?
Prediabetes and diabetes are usually assessed with HbA1c, fasting plasma glucose or an oral glucose-tolerance test. NIDDK notes that direct testing for insulin resistance is used mainly in research.[3]
If you have a glucose-related concern, the discussion should include existing results, medicines and the exact supplement being considered. The evidence should explain whether it concerns safety monitoring, a research signal or a demonstrated treatment effect. Those are three different reasons for looking at the same part of metabolism.
